ITP
JAZZ icon

Iron Triangle Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Iron Triangle Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$49.7M Buy
292,170
+142,170
+95% +$21.8M 5.68% 4
2025
Q3 		$19.8M Buy
+150,000
New +$18M 2.81% 17
2025
Q2 		– Sell
-130,000
Closed -$16.1M – 33
2025
Q1 		$16.1M Buy
+130,000
New +$17M 2.54% 21

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Iron Triangle Partners's JAZZ Position: Q4 2025 in Review

Iron Triangle Partners increased its Jazz Pharmaceuticals (JAZZ) stake by 95% in Q4 2025, buying an estimated $21.8M and bringing the position to 292,170 shares worth $49.7M. The position accounts for 5.68% of the portfolio, ranked #4.

Iron Triangle Partners first reported a position in JAZZ in Q1 2025 and has held it in 3 quarters since. 573 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

  • Iron Triangle Partners held 292,170 shares of Jazz Pharmaceuticals worth $49.7M as of Q4 2025.
  • Iron Triangle Partners bought 142,170 Jazz Pharmaceuticals shares in Q4 2025, an estimated $21.8M.
  • Jazz Pharmaceuticals made up 5.68% of Iron Triangle Partners's portfolio in Q4 2025, its #4 holding.
  • Iron Triangle Partners first reported a position in Jazz Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • 573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on Iron Triangle Partners's 13F filing for Q4 2025, filed 17 Feb 2026.